Vivos says study shows Vida oral appliance cuts insomnia severity in all 37 patients

Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc.

VVOS

0.00
  • Vivos Therapeutics released results from a single-site clinical study run between 2022 and 2025 of its FDA-cleared Vida oral appliance.
  • The study showed insomnia symptoms improved in all participants, with patients moving to lower severity categories by the end of treatment.
  • Management framed the findings as an entry point into the large insomnia market, with a near-term focus on patients with insomnia alongside sleep apnea.
  • The company projected an annual addressable market of about USD 36 million from new insomnia-related patients at its Sleep Centers of Nevada operation.
  • Vivos highlighted existing manufacturing capacity, testing equipment, and provider network as supports for a broader commercial rollout if results hold up.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300845PRIMZONEFULLFEED9754731) on June 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.